Shabir Madhi to Antibodies, Monoclonal, Humanized
This is a "connection" page, showing publications Shabir Madhi has written about Antibodies, Monoclonal, Humanized.
Connection Strength
1,921
-
The bronchiolitis season is upon us--recommendations for the management and prevention of acute viral bronchiolitis. S Afr Med J. 2015 Sep 21; 105(7):525-6.
Score: 0,471
-
A Phase 1b/2a Trial of a Half-life Extended Respiratory Syncytial Virus Neutralizing Antibody, Clesrovimab, in Healthy Preterm and Full-term Infants. J Infect Dis. 2025 Mar 17; 231(3):e478-e487.
Score: 0,227
-
Molecular and phenotypic characteristics of respiratory syncytial virus isolates recovered from medically vulnerable children: An exploratory analysis of a phase 2/3 randomized, double-blind, palivizumab-controlled trial of nirsevimab (MEDLEY). Vaccine. 2024 Oct 24; 42(24):126276.
Score: 0,219
-
Nirsevimab for Prevention of RSV in Term and Late-Preterm Infants. N Engl J Med. 2023 04 20; 388(16):1533-1534.
Score: 0,198
-
Nirsevimab for Prevention of RSV in Healthy Late-Preterm and Term Infants. N Engl J Med. 2022 03 03; 386(9):837-846.
Score: 0,184
-
Safety of Nirsevimab for RSV in Infants with Heart or Lung Disease or Prematurity. N Engl J Med. 2022 03 03; 386(9):892-894.
Score: 0,184
-
Single-dose nirsevimab prevents RSV infection. J Pediatr. 2021 01; 228:310-313.
Score: 0,170
-
Single-Dose Nirsevimab for Prevention of RSV in Preterm Infants. N Engl J Med. 2020 07 30; 383(5):415-425.
Score: 0,165
-
Infants Receiving a Single Dose of Nirsevimab to Prevent RSV Do Not Have Evidence of Enhanced Disease in Their Second RSV Season. J Pediatric Infect Dis Soc. 2024 Feb 26; 13(2):144-147.
Score: 0,053
-
Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials. Nat Commun. 2023 07 19; 14(1):4347.
Score: 0,051